Jennifer K Quint

List of Publications by Year
in descending order

224 papers	6,970 citations	71102 41 h-index	82547 72 g-index
246 all docs	246 docs citations	246 times ranked	9394 citing authors

#	Article	IF	Citations
1	Relationship between asthma and severe COVID-19: a national cohort study. Thorax, 2023, 78, 120-127.	5.6	26
2	Does pay-for-performance improve patient outcomes in acute exacerbation of COPD admissions?. Thorax, 2022, 77, 239-246.	5.6	5
3	COPD Epidemiology. , 2022, , 515-525.		1
4	Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients. Journal of Cardiac Failure, 2022, 28, 353-366.	1.7	11
5	Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. Annals of Epidemiology, 2022, 67, 19-28.	1.9	3
6	Respiratory-related death in individuals with incident asthma and COPD: a competing risk analysis. BMC Pulmonary Medicine, 2022, 22, 28.	2.0	7
7	Deriving a Standardised Recommended Respiratory Disease Codelist Repository for Future Research. Journal of Pragmatic and Observational Research, 2022, Volume 13, 1-8.	1.5	2
8	Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2297-2309.e10.	3.8	35
9	Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme. Advances in Therapy, 2022, 39, 2270-2280.	2.9	12
10	New insights into the optimal management of COPD: Extracts from CHEST 2021 annual meeting (October 17â€“20, 2021). Expert Review of Respiratory Medicine, 2022, , .	2.5	2
11	Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. International Journal of COPD, 2022, Volume 17, 427-437.	2.3	29
12	Variation in global COVID-19 symptoms by geography and by chronic disease: A global survey using the COVID-19 Symptom Mapper. EClinicalMedicine, 2022, 45, 101317.	7.1	11
13	Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax, 2022, 77, 717-720.	5.6	16
14	â€œNEWS2â€•as an Objective Assessment of Hospitalised COPD Exacerbation Severity. International Journal of COPD, 2022, Volume 17, 763-772.	2.3	4
15	Differences in Outcomes between Heart Failure Phenotypes in Patients with Coexistent Chronic Obstructive Pulmonary Disease: A Cohort Study. Annals of the American Thoracic Society, 2022, 19, 971-980.	3.2	8
16	A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1271-1280.	5.6	19
17	Left-sided heart failure burden and mortality in idiopathic pulmonary fibrosis: a population-based study. BMC Pulmonary Medicine, 2022, 22, 190.	2.0	2
18	Costâ€“consequence analysis of COPD treatment according to NICE and GOLD recommendations compared with current clinical practice in the UK. BMJ Open, 2022, 12, e059158.	1.9	3

#	Article	IF	Citations
19	Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database. Lancet Regional Health - Europe, The, 2022, 19, 100428.	5.6	18
20	Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England. Vascular Medicine, 2022, 27, 440-449.	1.5	2
21	Inhaled Corticosteroid Withdrawal and Change in Lung Function in Primary Care Patients with Chronic Obstructive Pulmonary Disease in England. Annals of the American Thoracic Society, 2022, 19, 1834-1841.	3.2	5
22	Impact of COPD and asthma on in-hospital mortality and management of patients with heart failure in England and Wales: an observational analysis. BMJ Open, 2022, 12, e059122.	1.9	4
23	Frailty in COPD: an analysis of prevalence and clinical impact using UK Biobank. BMJ Open Respiratory Research, 2022, 9, e001314.	3.0	21
24	Understanding the relationships between environmental factors and exacerbations of COPD. Expert Review of Respiratory Medicine, 2021, 15, 39-50.	2.5	16
25	The Role of Individual and Neighborhood Factors on Racial Disparity in Respiratory Outcomes. Wonâ€™t You Be My Neighbor?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 939-940.	5.6	0
26	Development and Validation of a Method to Estimate COPD Severity in Multiple Datasets: A Retrospective Study. Pulmonary Therapy, 2021, 7, 119-132.	2.2	0
27	Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. European Respiratory Journal, 2021, 57, 2001586.	6.7	11
28	Accelerated FEV₁decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. European Respiratory Journal, 2021, 57, 2000918.	6.7	24
29	Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people. Thorax, 2021, 76, 714-722.	5.6	105
30	Feasibility of using Clinical Practice Research Datalink data to identify patients with chronic obstructive pulmonary disease to enrol into realâ€world trials. Pharmacoepidemiology and Drug Safety, 2021, 30, 472-481.	1.9	6
31	Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respiratory Research, 2021, 22, 25.	3.6	15
32	Increased Mortality Risk in Patients With Primary and Secondary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2759-e2768.	3.6	34
33	Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respiratory Research, 2021, 22, 64.	3.6	29
34	Personal exposure to air pollution and respiratory health of COPD patients in London. European Respiratory Journal, 2021, 58, 2003432.	6.7	20
35	Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. International Journal of COPD, 2021, Volume 16, 321-332.	2.3	18
36	Cardiovascular Disease in Patients With Primary and Secondary Adrenal Insufficiency and the Role of Comorbidities. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1284-1293.	3.6	11

#	Article	IF	Citations
37	UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health, 2021, 21, 484.	2.9	25
38	Effectiveness and Safety of COPD Maintenance Therapy withÂTiotropium/Olodaterol versus LABA/ICS in a US Claims Database. Advances in Therapy, 2021, 38, 2249-2270.	2.9	7
39	Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data. Thorax, 2021, 76, 860-866.	5.6	69
40	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. International Journal of COPD, 2021, Volume 16, 841-851.	2.3	6
41	The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study. International Journal of COPD, 2021, Volume 16, 629-642.	2.3	1
42	COPD: still an unpredictable journey. European Respiratory Journal, 2021, 57, 2002933.	6.7	1
43	The Impact of the COVID-19 Pandemic on the Uptake of Influenza Vaccine: UK-Wide Observational Study. JMIR Public Health and Surveillance, 2021, 7, e26734.	2.6	56
44	Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study. The Lancet Digital Health, 2021, 3, e217-e230.	12.3	220
45	Relationship between heart failure and the risk of acute exacerbation of COPD. Thorax, 2021, 76, 807-814.	5.6	12
46	Burden of preschool wheeze and progression to asthma in the UK: Population-based cohort 2007 to 2017. Journal of Allergy and Clinical Immunology, 2021, 147, 1949-1958.	2.9	30
47	Mechanisms Underlying the Association of Chronic Obstructive Pulmonary Disease With HeartÂFailure. JACC: Cardiovascular Imaging, 2021, 14, 1963-1973.	5.3	12
48	Chronic Obstructive Pulmonary Disease (COPD) in Population Studies in Russia and Norway: Comparison of Prevalence, Awareness and Management. International Journal of COPD, 2021, Volume 16, 1353-1368.	2.3	3
49	Mortality Risk in Patients With Adrenal Insufficiency Using Prednisolone or Hydrocortisone: A Retrospective Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2242-2251.	3.6	6
50	Clinical and methodological considerations when interpreting meta-analyses of beta-blocker use in patients with chronic obstructive pulmonary disease. European Heart Journal, 2021, 42, 3407-3408.	2.2	3
51	Realising the full potential of data-enabled trials in the UK: a call for action. BMJ Open, 2021, 11, e043906.	1.9	23
52	Predicting Future Health Risk in COPD: Differential Impact of Disease-Specific and Multi-Morbidity-Based Risk Stratification. International Journal of COPD, 2021, Volume 16, 1741-1754.	2.3	6
53	Identifying COPD in routinely collected electronic health records: a systematic scoping review. ERJ Open Research, 2021, 7, 00167-2021.	2.6	2
54	Under-recognition of heart failure in patients with atrial fibrillation and the impact of gender: a UK population-based cohort study. BMC Medicine, 2021, 19, 179.	5.5	5

#	Article	IF	Citations
55	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. Lancet Respiratory Medicine,the, 2021, 9, 1467-1478.	10.7	84
56	Addressing a system failure to diagnose COPD and asthma. Lancet Respiratory Medicine,the, 2021, 9, 814-816.	10.7	0
57	Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. Health Technology Assessment, 2021, 25, 1-70.	2.8	0
58	Research priorities for exacerbations of COPD. Lancet Respiratory Medicine,the, 2021, 9, 824-826.	10.7	28
59	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.5	32
60	Challenges and Pitfalls of Using Repeat Spirometry Recordings in Routine Primary Care Data to Measure FEV1 Decline in a COPD Population. Journal of Pragmatic and Observational Research, 2021, Volume 12, 119-130.	1.5	0
61	Determinants of Shielding Behavior During the COVID-19 Pandemic and Associations With Well-being Among National Health Service Patients: Longitudinal Observational Study. JMIR Public Health and Surveillance, 2021, 7, e30460.	2.6	7
62	Predictors of pulmonary rehabilitation completion in the UK. ERJ Open Research, 2021, 7, 00509-2020.	2.6	8
63	EFFECTIVENESS OF COPD MAINTENANCE THERAPY WITH LAMA/LABA VS LAMA/LABA/ICS IN A UNITED STATES CLAIMS DATABASE. Chest, 2021, 160, A1863-A1864.	0.8	2
64	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. PLoS ONE, 2021, 16, e0258689.	2.5	2
65	A semi-supervised approach for rapidly creating clinical biomarker phenotypes in the UK Biobank using different primary care EHR and clinical terminology systems. JAMIA Open, 2021, 3, 545-556.	2.0	8
66	Patient symptoms and experience following COVID-19: results from a UK-wide survey. BMJ Open Respiratory Research, 2021, 8, e001075.	3.0	51
67	Concordance in the recording of stroke across UK primary and secondary care datasets: a population-based cohort study. BJGP Open, 2021, 5, BJGPO.2020.0117.	1.8	4
68	GP consultation rates for sequelae after acute covid-19 in patients managed in the community or hospital in the UK: population based study. BMJ, The, 2021, 375, e065834.	6.0	36
69	Eligibility for Lung Volume Reduction Surgery in Patients With COPD Identified in a UK Primary Care Setting. Chest, 2020, 157, 276-285.	0.8	13
70	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006â€“2015. European Heart Journal, 2020, 41, 1636-1649.	2.2	36
71	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	5.6	171
72	Prescribing Pathways to Triple Therapy: A Multi-Country, Retrospective Observational Study of Adult Patients with Chronic Obstructive Pulmonary Disease. Pulmonary Therapy, 2020, 6, 333-350.	2.2	15

#	Article	IF	Citations
73	National clinical audit for hospitalised exacerbations of COPD. ERJ Open Research, 2020, 6, 00208-2020.	2.6	15
74	Predictors of Referral to Pulmonary Rehabilitation from UK Primary Care . International Journal of COPD, 2020, Volume 15, 2941-2952.	2.3	24
75	Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease . International Journal of COPD, 2020, Volume 15, 3079-3091.	2.3	15
76	Methodologic Issues With Comparative Effectiveness Study on LAMA-LABA-ICS vsÂLAMA-LABA for the Treatment of COPD in the Clinical Practice Research Datalink. Chest, 2020, 158, 831-832.	0.8	0
77	Health and cost impact of stepping down asthma medication for UK patients, 2001â€“2017: A population-based observational study. PLoS Medicine, 2020, 17, e1003145.	8.4	19
78	Prediction of five-year mortality after COPD diagnosis using primary care records. PLoS ONE, 2020, 15, e0236011.	2.5	6
79	Asthma-Related Health Outcomes Associated with Short-Acting Î²2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. Advances in Therapy, 2020, 37, 4190-4208.	2.9	66
80	Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respiratory Medicine,the, 2020, 8, 1106-1120.	10.7	211
81	Using routine health data for research: the devil is in the detail. Thorax, 2020, 75, 714-715.	5.6	2
82	Belief of having had unconfirmed Covid-19 infection reduces willingness to participate in app-based contact tracing. Npj Digital Medicine, 2020, 3, 146.	10.9	27
83	Prescribing Pathways to Triple Therapy: A Retrospective Observational Study of Adults with Chronic Obstructive Pulmonary Disease in the UK . International Journal of COPD, 2020, Volume 15, 3261-3271.	2.3	6
84	Validation of acute exacerbation of chronic obstructive pulmonary disease (COPD) recording in electronic health records: a systematic review protocol. BMJ Open, 2020, 10, e032467.	1.9	2
85	Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respiratory Research, 2020, 21, 54.	3.6	28
86	SABINA: An Overview of Short-Acting Î²2-Agonist Use in Asthma in European Countries. Advances in Therapy, 2020, 37, 1124-1135.	2.9	84
87	Improving outcomes for children with asthma: role of national audit. Archives of Disease in Childhood, 2020, 105, 919-920.	1.9	2
88	Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK. European Respiratory Journal, 2020, 55, 1902363.	6.7	38
89	Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study . International Journal of COPD, 2020, Volume 15, 701-710.	2.3	10
90	Temporal Trends in the Incidence of Heart Failure among Patients with Chronic Obstructive Pulmonary Disease and Its Association with Mortality. Annals of the American Thoracic Society, 2020, 17, 939-948.	3.2	11

#	Article	IF	Citations
91	Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMJ Open, 2020, 10, e036455.	1.9	6
92	Lung volume reduction eligibility in patients with COPD completing pulmonary rehabilitation: results from the UK National Asthma and COPD Audit Programme. BMJ Open, 2020, 10, e040942.	1.9	8
93	Title is missing!. , 2020, 17, e1003145.		0
94	Title is missing!. , 2020, 17, e1003145.		0
95	Title is missing!. , 2020, 17, e1003145.		0
96	Title is missing!. , 2020, 17, e1003145.		0
97	Title is missing!. , 2020, 17, e1003145.		0
98	Reply to letter to the editor by Dr. Jolobe. International Journal of Cardiology, 2019, 292, 161.	1.7	0
99	Incidence of type II diabetes in chronic obstructive pulmonary disease: a nested caseâ€“control study. Npj Primary Care Respiratory Medicine, 2019, 29, 28.	2.6	14
100	Building toolkits for COPD exacerbations: lessons from the past and present. Thorax, 2019, 74, 898-905.	5.6	34
101	Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax, 2019, 74, 1078-1086.	5.6	22
102	Epidemiology of bronchiectasis in the UK: Findings from the British lung foundationâ€™s â€˜Respiratory health of the nationâ€™ project. Respiratory Medicine, 2019, 158, 21-23.	2.9	25
103	Non-communicable diseases in sub-Saharan Africa: a scoping review of large cohort studies. Journal of Global Health, 2019, 9, 020409.	2.7	68
104	National Asthma and COPD Audit Programme and the NHS Long Term Plan. Lancet Respiratory Medicine,the, 2019, 7, 841.	10.7	5
105	Outcome measures in a combined exercise rehabilitation programme for adults with COPD and chronic heart failure: A preliminary stakeholder consensus event. Chronic Respiratory Disease, 2019, 16, 147997311986795.	2.4	6
106	Air Pollution Monitoring for Health Research and Patient Care. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, 1207-1214.	3.2	25
107	Characterising low-cost sensors in highly portable platforms to quantify personal exposure in diverse environments. Atmospheric Measurement Techniques, 2019, 12, 4643-4657.	3.1	74
108	Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016 . International Journal of COPD, 2019, Volume 14, 279-287.	2.3	27

#	Article	IF	Citations
109	Changing causes of death for patients with chronic respiratory disease in England, 2005-2015. Thorax, 2019, 74, 483-491.	5.6	26
110	Clinical profile of predefined asthma phenotypes in a large cohort of UK primary care patients (Clinical Practice Research Datalink). Journal of Asthma and Allergy, 2019, Volume 12, 7-19.	3.4	6
111	Inhaled corticosteroids, blood eosinophils, and FEV₁ decline in patients with COPD in a large UK primary health care setting . International Journal of COPD, 2019, Volume 14, 1063-1073.	2.3	14
112	Unscheduled hospital contacts after inpatient discharge: A national observational study of COPD and heart failure patients in England. PLoS ONE, 2019, 14, e0218128.	2.5	3
113	Improved aerosol correction for OMI tropospheric NO₂ retrieval over East Asia: constraint from CALIOP aerosol vertical profile. Atmospheric Measurement Techniques, 2019, 12, 1-21.	3.1	75
114	Code sets for respiratory symptoms in electronic health records research: a systematic review protocol. BMJ Open, 2019, 9, e025965.	1.9	4
115	An observational cohort study of exercise and education for people with chronic obstructive pulmonary disease not meeting criteria for formal pulmonary rehabilitation programmes. Chronic Respiratory Disease, 2019, 16, 147997311983828.	2.4	6
116	Impact of chronic obstructive pulmonary disease on readmission after hospitalization for acute heart failure: A nationally representative US cohort study. International Journal of Cardiology, 2019, 290, 113-118.	1.7	14
117	How to validate a diagnosis recorded in electronic health records. Breathe, 2019, 15, 64-68.	1.3	25
118	Patterns of breathlessness and associated consulting behaviour: results of an online survey. Thorax, 2019, 74, 814-817.	5.6	22
119	Chronic obstructive pulmonary disease and myocardial infarction: when will we get our act together?. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 6, 1-2.	4.0	1
120	Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Groupâ€"European Academy of Allergy and Clinical Immunology Task Force. Clinical and Translational Allergy, 2019, 9, 20.	3.2	20
121	The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clinical and Translational Allergy, 2019, 9, 21.	3.2	24
122	Paediatric and adult bronchiectasis: Diagnosis, disease burden and prognosis. Respirology, 2019, 24, 413-422.	2.3	20
123	Protocol for a systematic literature review and network meta-analysis of the clinical benefit of inhaled maintenance therapies in chronic obstructive pulmonary disease. BMJ Open, 2019, 9, e025048.	1.9	4
124	Canâ€™t see the wood for the trees: confounders, colliders and causal inference - a clinicianâ€™s approach. Thorax, 2019, 74, 321-322.	5.6	2
125	Changing prevalence of current asthma and inhaled corticosteroid treatment inÂthe UK: population-based cohort 2006â€"2016. European Respiratory Journal, 2019, 53, 1802130.	6.7	50
126	Completeness and validity of alcohol recording in general practice within the UK: a cross-sectional study. BMJ Open, 2019, 9, e031537.	1.9	14

#	Article	IF	Citations
127	Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia. BMC Pulmonary Medicine, 2019, 19, 254.	2.0	18
128	Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review. Respiratory Research, 2019, 20, 277.	3.6	8
129	Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 117-124.	2.9	19
130	Exacerbation Patterns in Adults with Asthma in England. A Population-based Study. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 446-453.	5.6	63
131	Low uptake of palliative care for COPD patients within primary care in the UK. European Respiratory Journal, 2018, 51, 1701879.	6.7	66
132	Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practiceâ€“based Population with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 464-471.	5.6	122
133	External validation of ADO, DOSE, COTE and CODEX at predicting death in primary care patients with COPD using standard and machine learning approaches. Respiratory Medicine, 2018, 138, 150-155.	2.9	24
134	Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. Thorax, 2018, 73, 877-879.	5.6	21
135	COPD exacerbations: transforming outcomes through research. Lancet Respiratory Medicine,the, 2018, 6, 172-174.	10.7	3
136	Defining the relationship between COPD and CVD: what are the implications for clinical practice?. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346581775052.	2.6	186
137	Cardiovascular Outcomes after a Respiratory Tract Infection among Adults with Nonâ€“Cystic Fibrosis Bronchiectasis: A General Populationâ€“based Study. Annals of the American Thoracic Society, 2018, 15, 315-321.	3.2	23
138	Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. BMJ Open, 2018, 8, e019475.	1.9	6
139	Presentation, management and mortality after a first MI in people with and without asthma: A study using UK MINAP data. Chronic Respiratory Disease, 2018, 15, 60-70.	2.4	7
140	Exacerbation risk and characterisation of the UKâ€™s asthma population from infants to old age. Thorax, 2018, 73, 313-320.	5.6	123
141	Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison. BMJ Open, 2018, 8, e024736.	1.9	2
142	Concomitant diagnosis of asthma and COPD: a quantitative study in UK primary care. British Journal of General Practice, 2018, 68, e775-e782.	1.4	31
143	Mortality after admission for heart failure in the UK compared with Japan. Open Heart, 2018, 5, e000811.	2.3	10
144	Cottage by the sea or house above the trees: which is better for my lungs?. Thorax, 2018, 73, 1103-1104.	5.6	0

#	Article	IF	Citations
145	Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2018, 15, 935-946.	3.2	52
146	Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. European Journal of Heart Failure, 2018, 20, 1179-1190.	7.1	21
147	Response. Chest, 2018, 153, 1282-1283.	0.8	0
148	Hospitalisation and mortality outcomes of patients with comorbid COPD and heart failure: a systematic review protocol. BMJ Open, 2018, 8, e023058.	1.9	3
149	Nontuberculous mycobacterial disease managed within UK primary care, 2006â€“2016. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1795-1803.	2.9	16
150	Recruitment of patients with Chronic Obstructive Pulmonary Disease (COPD) from the Clinical Practice Research Datalink (CPRD) for research. Npj Primary Care Respiratory Medicine, 2018, 28, 21.	2.6	9
151	Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. Wellcome Open Research, 2018, 3, 67.	1.8	40
152	Preliminary results from the COPE study using primary-care electronic health records and environmental modelling to examine COPD exacerbations. British Journal of General Practice, 2018, 68, bjgp18X696749.	1.4	2
153	Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. Wellcome Open Research, 2018, 3, 67.	1.8	29
154	Asthma and lung cancer, after accounting for co-occurring respiratory diseases and allergic conditions: a systematic review protocol. BMJ Open, 2017, 7, e013637.	1.9	5
155	Thinking outside the lungs: â€˜otherâ€™ risk factors for pneumonia hospitalisation. Thorax, 2017, 72, 596.2-597.	5.6	0
156	Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax, 2017, 72, 161-166.	5.6	60
157	Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Annals of the American Thoracic Society, 2017, 14, 754-765.	3.2	21
158	Effects of Pulmonary Rehabilitation on Exacerbation Number and Severity in PeopleÂWith COPD. Chest, 2017, 152, 1188-1202.	0.8	31
159	Smoking cessation and COPD: further evidence is more necessary than ever. European Respiratory Journal, 2017, 49, 1700466.	6.7	1
160	Validation of asthma recording in electronic health records: protocol for a systematic review. BMJ Open, 2017, 7, e014694.	1.9	8
161	Association between childhood allergic diseases, educational attainment and occupational status in later life: systematic review protocol. BMJ Open, 2017, 7, e017245.	1.9	5
162	Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open, 2017, 7, e017474.	1.9	76

#	Article	IF	Citations
163	Prognostic variables and scores identifying the end of life in COPD: a systematic review. International Journal of COPD, 2017, Volume 12, 2239-2256.	2.3	36
164	Validation of asthma recording in electronic health records: a systematic review. Clinical Epidemiology, 2017, Volume 9, 643-656.	3.0	31
165	Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care. International Journal of COPD, 2017, Volume 12, 1663-1668.	2.3	41
166	Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health records. BMJ Open Diabetes Research and Care, 2017, 5, e000332.	2.8	14
167	The Air We Breathe: Effect of Environmental Exposures on COPD. Tanaffos, 2017, 16, S14-S15.	0.5	1
168	No association between exacerbation frequency and stroke in patients with COPD. International Journal of COPD, 2016, 11, 217.	2.3	6
169	Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clinical Epidemiology, 2016, Volume 8, 771-782.	3.0	65
170	COPD disease severity and the risk of venous thromboembolic events: a matched case–control study. International Journal of COPD, 2016, 11, 899.	2.3	17
171	Prognostic variables and scores identifying the last year of life in COPD: a systematic review protocol. BMJ Open, 2016, 6, e011677.	1.9	2
172	Asthma hospitalisations and air pollution. Thorax, 2016, 71, 1076-1077.	5.6	2
173	Linking e-health records, patient-reported symptoms and environmental exposure data to characterise and model COPD exacerbations: protocol for the COPE study. BMJ Open, 2016, 6, e011330.	1.9	17
174	Chronic obstructive pulmonary disease and the risk of stroke: a systematic review protocol. BMJ Open, 2016, 6, e011898.	1.9	7
175	Improved incidence estimates from linked vs. stand-alone electronic health records. Journal of Clinical Epidemiology, 2016, 75, 66-69.	5.0	31
176	Cardiovascular disease in COPD: time to quash a silent killer. Lancet Respiratory Medicine,the, 2016, 4, 687-689.	10.7	8
177	Pulmonary Rehabilitation as a Mechanism to Reduce Hospitalizations for Acute Exacerbations of COPD. Chest, 2016, 150, 837-859.	0.8	60
178	Trends in mortality from respiratory system diseases in Greece during the financial crisis. European Respiratory Journal, 2016, 48, 1487-1489.	6.7	7
179	Predicting mortality after acute coronary syndromes in people with chronic obstructive pulmonary disease. Heart, 2016, 102, 1442-1448.	2.9	10
180	CT-diagnosed emphysema and lung cancer mortality: novel association or old news?. Thorax, 2016, 71, 583-584.	5.6	0

#	Article	IF	Citations
181	Global Associations between Air Pollutants and Chronic Obstructive Pulmonary Disease Hospitalizations: A Systematic Review. Annals of the American Thoracic Society, 2016, 13, 1814-1827.	3.2	43
182	Diagnosis of acute kidney injury and its association with in-hospital mortality in patients with infective exacerbations of bronchiectasis: cohort study from a UK nationwide database. BMC Pulmonary Medicine, 2016, 16, 14.	2.0	11
183	Measuring cardiovascular risk in COPD; childâ€™s play or MENSA?. Chronic Respiratory Disease, 2016, 13, 209-210.	2.4	0
184	Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 81-90.	4.0	18
185	Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. European Respiratory Journal, 2016, 47, 186-193.	6.7	393
186	Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records. PLoS ONE, 2016, 11, e0151357.	2.5	117
187	Risk factors for hospital admission in the 28â€…days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. BMJ Open, 2015, 5, e008737.	1.9	40
188	Self-reported symptoms of chronic cough and breathlessness in working-age men in the city of Izhevsk, Russia: associations with cardiovascular disease risk factors and comorbidities. BMJ Open Respiratory Research, 2015, 2, e000104.	3.0	3
189	Acute kidney injury in stable COPD and at exacerbation. International Journal of COPD, 2015, 10, 2067.	2.3	38
190	Are clinical risk scores for COPD useful?. BMJ Open Respiratory Research, 2015, 2, e000072.	3.0	1
191	Pulmonary rehabilitation and severe exacerbations of COPD: solution or white elephant?. ERJ Open Research, 2015, 1, 00050-2015.	2.6	22
192	Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart, 2015, 101, 1103-1110.	2.9	61
193	Systemic manifestations of chronic obstructive pulmonary disease. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, 324-329.	0.5	5
194	Cardiotoxicity during Invasive Pneumococcal Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 739-745.	5.6	70
195	Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open, 2015, 5, e007824.	1.9	66
196	GRACE scores in COPD patients with acute coronary syndromes: Performance and impact on secondary prevention. , 2015, , .		1
197	Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open, 2014, 4, e005540-e005540.	1.9	203
198	Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L311-L316.	2.9	12

#	Article	IF	Citations
199	The WISDOM of inhaled corticosteroids in COPD. Thorax, 2014, 69, 1071-1072.	5.6	8
200	Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open, 2014, 4, e006171.	1.9	97
201	Author's reply to Wolstenholme and Sanfilippo and colleagues. BMJ, The, 2014, 348, g1132-g1132.	6.0	0
202	Weighing up risk factors for pneumonia: the role of mental illness and benzodiazepine use. Thorax, 2013, 68, 121-122.	5.6	1
203	Keeping â€˜a chestâ€™ of the literature. Thorax, 2013, 68, 610-610.	5.6	0
204	Incidence of Community-Acquired Lower Respiratory Tract Infections and Pneumonia among Older Adults in the United Kingdom: A Population-Based Study. PLoS ONE, 2013, 8, e75131.	2.5	137
205	Call for reviewers for journal club in Thorax. Thorax, 2012, 67, 116-116.	5.6	0
206	Pneumonia in the Nonâ€“HIV-Infected Immunocompromised Patient. , 2012, , 330-345.		0
207	25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2012, 12, 28.	2.0	47
208	SERPINA1 11478G->A variant, serum Â1-antitrypsin, exacerbation frequency and FEV1 decline in COPD. Thorax, 2011, 66, 418-424.	5.6	9
209	Predictive accuracy of patient-reported exacerbation frequency in COPD. European Respiratory Journal, 2011, 37, 501-507.	6.7	69
210	Serum IP-10 as a Biomarker of Human Rhinovirus Infection at Exacerbation of COPD. Chest, 2010, 137, 812-822.	0.8	101
211	Use and utility of a 24-hour Telephone Support Service for â€˜high riskâ€™ patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 260-265.	2.3	18
212	Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulmonary Medicine, 2010, 10, 52.	2.0	78
213	Defective macrophage phagocytosis of bacteria in COPD. European Respiratory Journal, 2010, 35, 1039-1047.	6.7	301
214	Is vitamin D deficiency important in the natural history of COPD?. Thorax, 2010, 65, 192-194.	5.6	13
215	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 369-374.	5.6	231
216	Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 2009, 103, 216-223.	2.9	107

#	Article	IF	Citations
217	Relationship between depression and exacerbations in COPD. European Respiratory Journal, 2008, 32, 53-60.	6.7	142
218	Respiratory Syncytial Virus Persistence in Chronic Obstructive Pulmonary Disease. Pediatric Infectious Disease Journal, 2008, 27, S63-S70.	2.0	84
219	Previously undiagnosed obesity hypoventilation syndrome. Thorax, 2007, 62, 462-463.	5.6	31
220	The neutrophil in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2007, 119, 1065-1071.	2.9	143
221	Impact of new home oxygen service on respiratory units. Thorax, 2006, 61, 830-830.	5.6	1
222	The challenge of palliative care. , 0, , 297-322.		1
223	Know Your Heart: Rationale, design and conduct of a cross-sectional study of cardiovascular structure, function and risk factors in 4500 men and women aged 35-69 years from two Russian cities, 2015-18. Wellcome Open Research, 0, 3, 67.	1.8	17
224	Genome-wide association study of susceptibility to hospitalised respiratory infections. Wellcome Open Research, 0, 6, 290.	1.8	3